---
title: "Guangdong Zhongsheng Pharmaceutical Subsidiary Receives FDA Approval for Peptide Clinical Trial"
date: "2025-02-10 17:05:11"
summary: "Guangdong Zhongsheng Pharmaceutical said its subsidiary, Zhongsheng Ruichuang Biotech, received FDA approval for a Phase II clinical trial of its innovative peptide drug RAY1225 injection in the US for treating obesity and overweight patients. RAY1225 is a GLP-1 and GIP receptor dual agonist with potential applications in diabetes and metabolic..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Guangdong Zhongsheng Pharmaceutical said its subsidiary, Zhongsheng Ruichuang Biotech, received FDA approval for a Phase II clinical trial of its innovative peptide drug RAY1225 injection in the US for treating obesity and overweight patients.

RAY1225 is a GLP-1 and GIP receptor dual agonist with potential applications in diabetes and metabolic disorders, according to a Saturday filing with the Shenzhen Bourse.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250210:G2465625:0/)
